XML 37 R27.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaboration Agreements - Accounting for the AstraZeneca Agreements - Additional Information 3 (Detail) - USD ($) | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Manufacturing commercial supplies of products, revenue recognized | $ 29,027,000 | $ 40,550,000 | $ 104,903,000 | $ 100,260,000
AstraZeneca Agreements [Member] |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Right-of-return provisions for delivered items |  |  | $ 0 |
Royalty rate against projected net revenues | 40.00% |  | 40.00% |
Co-development services, currently estimated continuation year |  |  | 2020 |
AstraZeneca Agreements [Member] | Manufacturing Commercial Supplies of Products [Member] |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Manufacturing commercial supplies of products, revenue recognized |  |  | $ 0 |
AstraZeneca Agreements [Member] | Measurement Input Discount Rate [Member] | Discounted Cash Flow [Member] |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Discount rate applied | 17.5 |  | 17.5 |
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Non-contingent upfront payments received |  |  | $ 402,200,000 |
Variable consideration related to payments for milestones considered probable of being achieved |  |  | 30,000,000 |
Variable consideration related to co-development billings |  |  | $ 669,700,000 |

X
- Definition Co-development services, estimated continuation year. + References No definition available. + Details
Name: | fgen_CoDevelopmentServicesEstimatedContinuationYear
Namespace Prefix: | fgen_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of non-contingent upfront payments included under the collaborative agreement as arrangement consideration. + References No definition available. + Details
Name: | fgen_ProceedsFromNonContingentUpfrontPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Implied royalty rate used to find the net present value of future cash flows. + References No definition available. + Details
Name: | fgen_RoyaltyRateOnNetRevenue
Namespace Prefix: | fgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Variable consideration payment received related to co-development billings. + References No definition available. + Details
Name: | fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Variable consideration payment received upon achievement of milestone. + References No definition available. + Details
Name: | fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Value of input used to measure alternative investment. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258 + Details
Name: | us-gaap_AlternativeInvestmentMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of estimated sales returns. + References Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790 + Details
Name: | us-gaap_RevenueRecognitionSalesReturnsReserveForSalesReturns
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldAndChinaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |